KIORA PHARMACEUTICALS, INC. Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Net
KIORA PHARMACEUTICALS, INC. (KPRX) had Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Net of $1.17 million as of 2021-10-21, per its 10-Q filed 2022-11-09.
Discontinued › Notes › Business Combination, Asset Acquisition, Transaction between Entities under Common Control, and Joint Venture Formation › Business Combination, Recognized Asset Acquired to Liability Assumed, Excess (Less)
us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet · last filed 2022-11-09
- 2021-10-21: Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Net $1.17M.
- 2016-09-30: Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Net $2.91M.
- 2016-06-30: Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Net $3.82M.
- 2016-03-31: Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Net $3.82M.
| Period end | Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Net |
|---|---|
| 2021-10-21 | $1.17M 10-Q · filed 2022-11-09 |
| 2016-09-30 | $2.91M 10-Q · filed 2016-11-01 |
| 2016-06-30 | $3.82M 10-Q · filed 2016-08-10 |
| 2016-03-31 | $3.82M 10-Q · filed 2016-05-13 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Scienture Holdings, Inc. (SCNX) | United States | $0.012B | -0.38 |
| Phio Pharmaceuticals Corp. (PHIO) | United States | $0.012B | -0.92 |
| ADIAL PHARMACEUTICALS, INC. (ADIL) | United States | $0.012B | |
| Dare Bioscience, Inc. (DARE) | United States | $0.011B | |
| BIOVIE INC. (BIVI) | United States | $0.012B | |
| Aspire Biopharma Holdings, Inc. (ASBP) | United States | $0.012B | -0.60 |
| Tempest Therapeutics, Inc. (TPST) | United States | $0.013B | |
| Moleculin Biotech, Inc. (MBRX) | United States | $0.011B | |
| MetaVia Inc. (MTVA) | United States | $0.011B | -0.65 |
| KALA BIO, Inc. (KALA) | United States | $0.011B | -3.33 |